Trending NewsTrending NewsTop-Rated Dividend StocksTop-Rated DividendNASDAQ:GILD Gilead Sciences (GILD) Stock Price, News & Analysis $130.69 +0.19 (+0.15%) Closing price 05/20/2026 04:00 PM EasternExtended Trading$130.10 -0.59 (-0.45%) As of 05/20/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Gilead Sciences Stock (NASDAQ:GILD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Gilead Sciences alerts:Sign Up Key Stats Today's Range$129.49▼$131.9550-Day Range$127.75▼$148.5652-Week Range$104.46▼$157.29Volume5.57 million shsAverage Volume6.24 million shsMarket Capitalization$162.26 billionP/E Ratio17.81Dividend Yield2.51%Price Target$156.93Consensus RatingModerate Buy Company Overview Gilead Sciences, Inc., founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world. Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis. Its marketed HIV medicines include combination regimens such as Biktarvy and older franchise products used for treatment and prevention. In hepatitis C, Gilead’s acquisitions and development efforts produced direct-acting antivirals including sofosbuvir-based regimens marketed under names such as Sovaldi, Harvoni and Epclusa. During the COVID-19 pandemic Gilead’s antiviral remdesivir (Veklury) became one of the first therapies authorized for treatment of hospitalized patients. In oncology and cell therapy, Gilead strengthened its pipeline and commercial footprint through acquisitions—most notably the purchase of Kite Pharma, which added CAR-T therapies including Yescarta and Tecartus, and the acquisition of Immunomedics, which added the antibody–drug conjugate Trodelvy—illustrating the company’s strategic shift to diversify beyond traditional antivirals. Historically, Gilead has grown through a combination of internal R&D and targeted acquisitions, including Pharmasset in 2011 (which accelerated its hepatitis C program) and later transactions that broadened its oncology and cell therapy capabilities. The company maintains research centers and commercial operations across North America, Europe, Asia and other regions, serving a global patient population. Michael L. Riordan founded Gilead, and the company’s executive leadership in recent years has overseen the transition from a primarily antivirals-focused developer to a broader biopharma company; as of mid-2024, Daniel O’Day was serving as the company’s chief executive. Gilead continues to invest in clinical development and strategic partnerships to expand its therapeutic offerings and address emerging medical needs.AI Generated. May Contain Errors. Read More Gilead Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks96th Percentile Overall ScoreGILD MarketRank™: Gilead Sciences scored higher than 96% of companies evaluated by MarketBeat, and ranked 20th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingGilead Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on no strong buy ratings, 25 buy ratings, 4 hold ratings, and no sell ratings.Upside PotentialGilead Sciences has a consensus price target of $156.93, representing about 20.1% upside from its current price of $130.69.Amount of Analyst CoverageGilead Sciences has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Gilead Sciences' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Gilead Sciences are expected to grow in the coming year, from ($0.77) to $9.62 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gilead Sciences is 17.81, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.53.Price to Earnings Ratio vs. SectorThe P/E ratio of Gilead Sciences is 17.81, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.04.Price to Book Value per Share RatioGilead Sciences has a P/B Ratio of 6.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Gilead Sciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted1.86% of the float of Gilead Sciences has been sold short.Short Interest Ratio / Days to CoverGilead Sciences has a short interest ratio ("days to cover") of 4.06.Change versus previous monthShort interest in Gilead Sciences has recently increased by 1.32%, indicating that investor sentiment is decreasing. Dividend4.2 / 5Dividend StrengthStrong Dividend YieldGilead Sciences pays a meaningful dividend of 2.51%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthGilead Sciences has been increasing its dividend for 10 years.Dividend CoverageThe dividend payout ratio of Gilead Sciences is 44.69%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Gilead Sciences will have a dividend payout ratio of 34.10% next year. This indicates that Gilead Sciences will be able to sustain or increase its dividend.Read more about Gilead Sciences' dividend. News and Social Media4.4 / 5News Sentiment1.01 News SentimentGilead Sciences has a news sentiment score of 1.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 53 news articles for Gilead Sciences this week, compared to 15 articles on an average week.Search Interest52 people have searched for GILD on MarketBeat in the last 30 days. This is an increase of 11% compared to the previous 30 days.MarketBeat Follows22 people have added Gilead Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 175% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Gilead Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,523,570.00 in company stock.Percentage Held by Insiders0.30% of the stock of Gilead Sciences is held by insiders.Percentage Held by Institutions83.67% of the stock of Gilead Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Gilead Sciences' insider trading history. Receive GILD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gilead Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GILD Stock News HeadlinesGilead Sciences Launches New $3 Billion Senior NotesMay 20 at 6:11 PM | tipranks.comCigna downgraded, Humana upgraded: Wall Street's top analyst callsMay 20 at 10:09 AM | finance.yahoo.comIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors. | American Alternative (Ad)5 Best Long Term Low Risk Stocks to Buy According to Hedge FundsMay 19 at 3:31 PM | insidermonkey.comGilead Sciences, Inc. (GILD) Presents at RBC Capital Markets Global Healthcare Conference 2026 TranscriptMay 19 at 2:00 PM | seekingalpha.com3 Market-Beating Stocks to Research FurtherMay 19 at 7:18 AM | finance.yahoo.comPolymyositis Market Research Report 2026-2036: Competitive Landscape is Dominated by Major Players Such As Teva Pharmaceuticals, Gilead Sciences, Roche, AbbVie, and PfizerMay 19 at 7:18 AM | finance.yahoo.comGilead Sciences (NASDAQ:GILD) CFO Sells $396,810.00 in StockMay 19 at 4:35 AM | insidertrades.comSee More Headlines GILD Stock Analysis - Frequently Asked Questions How have GILD shares performed this year? Gilead Sciences' stock was trading at $122.74 at the start of the year. Since then, GILD stock has increased by 6.5% and is now trading at $130.69. How were Gilead Sciences' earnings last quarter? Gilead Sciences, Inc. (NASDAQ:GILD) issued its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences's quarterly revenue was up 4.4% on a year-over-year basis. Read the conference call transcript. Does Gilead Sciences have any subsidiaries? The following companies are subsidiaries of Gilead Sciences: MYR, Immunomedics, Forty Seven, Cell Design Labs, Kite Pharma, Nimbus Apollo, Epitherapeutics, and more. Who are Gilead Sciences' major shareholders? Gilead Sciences' top institutional investors include Bank of America Corp DE (1.61%), Amundi (0.85%), Dimensional Fund Advisors LP (0.62%) and Swiss National Bank (0.29%). Insiders that own company stock include Daniel Patrick O'day, Andrew D Dickinson, Johanna Mercier, Merdad Parsey, Deborah H Telman, Jeffrey Bluestone and Kelly A Kramer. View institutional ownership trends. How do I buy shares of Gilead Sciences? Shares of GILD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Gilead Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Gilead Sciences investors own include Cuisine Solutions (CUSI), InnerScope Hearing Technologies (INND), Johnson & Johnson (JNJ), UnitedHealth Group (UNH), Corning (GLW), NextEra Energy (NEE) and American Tower (AMT). Company Calendar Record date for 3/30 Dividend3/13/2026Ex-Dividend for 3/30 Dividend3/13/2026Dividend Payable3/30/2026Last Earnings5/07/2026Today5/20/2026Bernstein 42nd Annual Strategic Decisions Conference5/28/2026Goldman Sachs 47th Annual Global Healthcare Conference 20266/09/2026Record date for 6/29 Dividend6/15/2026Ex-Dividend for 6/29 Dividend6/15/2026Dividend Payable6/29/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 GILD's financial health is in the Yellow zone, according to TradeSmith. GILD has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:GILD CIK882095 Webwww.gilead.com Phone(650) 574-3000Fax650-578-9264Employees17,000Year Founded1987Price Target and Rating Average Price Target for Gilead Sciences$156.93 High Price Target$180.00 Low Price Target$115.00 Potential Upside/Downside+20.1%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage29 Analysts Profitability EPS (Trailing Twelve Months)$7.34 Trailing P/E Ratio17.81 Forward P/E RatioN/A P/E GrowthN/ANet Income$8.51 billion Net Margins30.99% Pretax Margin36.07% Return on Equity48.19% Return on Assets18.28% Debt Debt-to-Equity Ratio0.89 Current Ratio1.97 Quick Ratio1.77 Sales & Book Value Annual Sales$29.44 billion Price / Sales5.51 Cash Flow$10.49 per share Price / Cash Flow12.46 Book Value$18.87 per share Price / Book6.93Miscellaneous Outstanding Shares1,241,570,000Free Float1,237,845,000Market Cap$162.26 billion OptionableOptionable Beta0.31 Social Links 7 Stocks to Ride The A.I. MegaboomWe are about to experience the greatest A.I. boom in stock market history... Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s. That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom. Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day. And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly... Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy. Get This Free Report This page (NASDAQ:GILD) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gilead Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gilead Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
